Evidence map›Paper›PMID 41704551›Full record

ArticleCurrent research in pharmacology and drug discovery2026

Anti-Shigella activity and killing kinetics of compounds from MMV Pathogen and COVID Boxes: Identifying leads against Shigellosis.

Lauve Rachel Tchokouaha Yamthe, Francine Kengne Mediesse, Yanick Kevin Melogmo Dongmo, Sonia Raissa Matchuenkam Gayap, Darline Dize, Patrick Valere Tsouh Fokou, Fabrice Fekam Boyom

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current research in pharmacology and drug discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lauve Rachel Tchokouaha YamtheInstitute of Medical Research and Medicinal Plants Studies, P.O.Box 13033, Yaounde, Cameroon.
Francine Kengne MediesseInstitute of Medical Research and Medicinal Plants Studies, P.O.Box 13033, Yaounde, Cameroon.
Yanick Kevin Melogmo DongmoDepartment of Biochemistry, Faculty of Science, University of Yaounde 1, P.O. Box 812, Yaounde, Cameroon.
Sonia Raissa Matchuenkam GayapInstitute of Medical Research and Medicinal Plants Studies, P.O.Box 13033, Yaounde, Cameroon.
Darline DizeDepartment of Biochemistry, Faculty of Science, University of Yaounde 1, P.O. Box 812, Yaounde, Cameroon.
Patrick Valere Tsouh FokouDepartment of Biochemistry, Faculty of Science, University of Yaounde 1, P.O. Box 812, Yaounde, Cameroon.
Fabrice Fekam BoyomDepartment of Biochemistry, Faculty of Science, University of Yaounde 1, P.O. Box 812, Yaounde, Cameroon.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Shigellosis is a leading diarrheal disease, posing critical public health challenges in low- and middle-income countries. Rising antibiotic resistance exacerbates treatment limitations. Methods: We screened 560 compounds from the MMV Pathogen and COVID Boxes for Results: From the primary screen, 13 compounds (9 from the Pathogen Box, 4 from the COVID Box) showed potent anti- Conclusion: This study identifies several novel, non-antibiotic leads from the MMV Pathogen Box with potent anti-

Indexed as

Antibacterial agentsCOVID BoxDrug repurposingMMV Pathogen BoxShigellosisTime-kill kinetics

Identifiers

PMID41704551
PMCPMC12907685

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.